Vaginal Progesterone for Treatment of Threatened Miscarriage
NCT ID: NCT02690129
Last Updated: 2016-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
290 participants
INTERVENTIONAL
2016-02-29
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Progesterone in Threatened Abortion
NCT02950935
Pr-conceptional Progesterone for Unexplained Recurrent Miscarriage
NCT01670929
Oral Progesterone for Prevention of Miscarriage in Threatened Abortion
NCT04788108
Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage
NCT02686840
Progesterone Supplementation in Threatened Abortion
NCT03930212
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I (Progesterone Group)
Complete bed rest as an in/or out- patient, according to patient's preference for first 48-72 hours.
* Vaginal progesterone treatment as single daily dose of natural micronized progesterone (Prontogest ® 200 mg) at bedtime for 15 days.
* If needed, a pain killer as Indomethacin 50 mg/ rectally twice daily up to control of uterine colic .
* Complete abstaining from sexual activity or strenuous effort. Additionally, Rh-ve women with established viable fetuses and continue bleeding will be given a shot of anti-D immunoglobulin 300 ugm/IM ; after 12 weeks' gestation or if undergo surgical evacuation.
Vaginal Progesteron
Group II ( Control group)
Will follow the same plan of management without progesterone support.
Vaginal Progesteron
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vaginal Progesteron
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Presented by bleeding with or without pain
3. Single viable fetus (confirmed by Ultrasound examination)
4. Accepting to have vaginal medication
Exclusion Criteria
2. Hypersensitivity to progesterone
3. Any documented congenital fetal anomaly in the current pregnancy
4. Women received hormonal treatment in the current pregnancy
5. Patients conceived via ART
20 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Omar Mamdouh Shaaban
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Omar Mamdouh Shaaban
Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine
Asyut, Asyut Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
treatment of miscarraige
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.